Impact of statin intake on malignant hyperthermia: an in vitro and in vivo swine study.
MHS swine
Malignant hyperthermia
Muscle disease
Statin medication
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
23 10 2020
23 10 2020
Historique:
received:
09
05
2020
accepted:
13
10
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
14
9
2021
Statut:
epublish
Résumé
Statin intake is associated with muscular side effects, among which the unmasking of latent myopathies and of malignant hyperthermia (MH) susceptibility have been reported. These findings, together with experimental data in small animals, prompt speculation that statin therapy may compromise the performance of skeletal muscle during diagnostic in vitro contracture tests (IVCT). In addition, statins might reduce triggering thresholds in susceptible individuals (MHS), or exacerbate MH progression. We sought to obtain empirical data to address these questions. We compared the responses of 3 different muscles from untreated or simvastatin treated MHS and non-susceptible (MHN) pigs. MHS animals were also invasively monitored for signs of impending MH during sevoflurane anesthesia. Muscles from statin treated MHS pigs responded with enhanced in vitro contractures to halothane, while responses to caffeine were unaltered by the treatment. Neither agent elicited contractures in muscles from statin treated MHN pigs. In vivo, end- tide pCO2, hemodynamic evolution, plasma pH, potassium and lactate concentrations consistently pointed to mild acceleration of MH development in statin-treated pigs, whereas masseter spasm and rigor faded compared to untreated MHS animals. The diagnostic sensitivity and specificity of the IVCT remains unchanged by a short-term simvastatin treatment in MHS swine. Evidence of modest enhancement in cardiovascular and metabolic signs of MH, as well as masked pathognomonic muscle rigor observed under simvastatin therapy suggest a potentially misleading influence on the clinical presentation of MH. The findings deserve further study to include other statins and therapeutic regimes.
Sections du résumé
BACKGROUND
Statin intake is associated with muscular side effects, among which the unmasking of latent myopathies and of malignant hyperthermia (MH) susceptibility have been reported. These findings, together with experimental data in small animals, prompt speculation that statin therapy may compromise the performance of skeletal muscle during diagnostic in vitro contracture tests (IVCT). In addition, statins might reduce triggering thresholds in susceptible individuals (MHS), or exacerbate MH progression. We sought to obtain empirical data to address these questions.
METHODS
We compared the responses of 3 different muscles from untreated or simvastatin treated MHS and non-susceptible (MHN) pigs. MHS animals were also invasively monitored for signs of impending MH during sevoflurane anesthesia.
RESULTS
Muscles from statin treated MHS pigs responded with enhanced in vitro contractures to halothane, while responses to caffeine were unaltered by the treatment. Neither agent elicited contractures in muscles from statin treated MHN pigs. In vivo, end- tide pCO2, hemodynamic evolution, plasma pH, potassium and lactate concentrations consistently pointed to mild acceleration of MH development in statin-treated pigs, whereas masseter spasm and rigor faded compared to untreated MHS animals.
CONCLUSIONS
The diagnostic sensitivity and specificity of the IVCT remains unchanged by a short-term simvastatin treatment in MHS swine. Evidence of modest enhancement in cardiovascular and metabolic signs of MH, as well as masked pathognomonic muscle rigor observed under simvastatin therapy suggest a potentially misleading influence on the clinical presentation of MH. The findings deserve further study to include other statins and therapeutic regimes.
Identifiants
pubmed: 33096987
doi: 10.1186/s12871-020-01186-5
pii: 10.1186/s12871-020-01186-5
pmc: PMC7585199
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Sevoflurane
38LVP0K73A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Références
Eur J Anaesthesiol. 2004 Jul;21(7):572-4
pubmed: 15318472
Br J Anaesth. 2019 Jan;122(1):32-41
pubmed: 30579404
Eur J Clin Pharmacol. 2015 Jan;71(1):117-24
pubmed: 25367069
J Pharmacol Exp Ther. 2007 May;321(2):626-34
pubmed: 17293561
Rheumatol Int. 2018 Feb;38(2):293-301
pubmed: 29027009
N Engl J Med. 2016 May 26;374(21):2021-31
pubmed: 27040132
N Engl J Med. 2009 Jan 15;360(3):304
pubmed: 19144951
Arthritis Rheum. 2006 Aug 15;55(4):551-7
pubmed: 16874775
Curr Opin Lipidol. 2015 Jun;26(3):221-7
pubmed: 25943841
Br J Pharmacol. 2018 Mar;175(6):938-952
pubmed: 29278865
Skelet Muscle. 2013 Sep 03;3(1):22
pubmed: 24004537
Br J Anaesth. 2015 Oct;115(4):531-9
pubmed: 26188342
Anesth Analg. 1994 Jul;79(1):143-51
pubmed: 8010426
Can J Cardiol. 2016 Jul;32(7 Suppl):S35-65
pubmed: 27342697
Ann Biomed Eng. 2018 Jul;46(7):947-959
pubmed: 29594687
Muscle Nerve. 2018 Jun;57(6):E138-E140
pubmed: 29350769
J Intern Med. 2005 Aug;258(2):196-7
pubmed: 16018797
Langmuir. 2012 Mar 13;28(10):4723-8
pubmed: 22352350
Biochem Biophys Res Commun. 2015 Oct 23;466(3):536-40
pubmed: 26381177
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
Br J Anaesth. 2011 Jul;107(1):48-56
pubmed: 21624965
N Engl J Med. 2016 Feb 18;374(7):664-9
pubmed: 26886523
Cardiovasc Ther. 2010 Dec;28(6):356-60
pubmed: 20955541
Toxicol Lett. 2019 Jun 1;307:49-58
pubmed: 30853469
Eur J Clin Invest. 2015 Jul;45(7):745-54
pubmed: 25991405
Atherosclerosis. 2009 Dec;207(2):384-90
pubmed: 19540496
Arch Intern Med. 2006 Jul 24;166(14):1519-24
pubmed: 16864763